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Diabetes mellitus is a group of metabolic diseases in 
which a person has high blood sugar, either because the 
pancreas does not produce enough insulin, or because 
cells do not respond to the insulin that is produced1. 
There are three main types of diabetes mellitus (DM). 
Type 1 DM results from the body's failure to produce 
insulin, and currently requires the person     to inject 
insulin or wear an insulin pump. This form was 
previously referred to as "insulin- dependent diabetes 
mellitus" (IDDM) or "juvenile diabetes". 
Type 2 DM results from insulin resistance, a condition in 
which cells fail to use insulin properly, sometimes 
combined with an absolute insulin deficiency. This form 
was previously referred to as non insulin-dependent 
diabetes mellitus (NIDDM) or "adult-onset diabetes". 
The third main form, gestational diabetes, occurs when 
pregnant women without a previous diagnosis of diabetes 
develop a high blood glucose level. It may precede 
development of type 2 DM. 
The main symptoms associated with diabetes mellitus are 
loss of weight, polyuria (frequent urination), polydipsia 
(increased thirst), and polyphagia (increased hunger) 2 .  
The main complications associated with diabetes 
mellitus are3: 
 Coronary heart disease, which can lead to a heart 
attack 
 Cerebrovascular disease, which can lead to stroke 
 Retinopathy (disease of the eye), which can lead to 
blindness 
 Nephropathy (disease of the kidney), which can lead 
to kidney failure and the need for dialysis 
 Neuropathy (disease of the nerves), which can lead 
to, among other things, ulceration of the foot. 
Diabetic nephropathy is a clinical syndrome 
characterized by albuminuria, hypertension, and 
progressive renal insufficiency4. It is characterized by 
nephrotic syndrome and diffuse glomerulosclerosis5. 
The main signs and symptoms of diabetes nephropathy 
are; 
 Albumin or protein in the urine  
 High blood pressure  
 Ankle and leg swelling, leg cramps 
 Morning sickness, nausea, and vomiting 
CASE REPORT; 
A 44 yrs old man was admitted to Malla Reddy-
Narayana medical college hospital and research center, 
Suraram with chief complaints of high blood pressure, 
ankle and leg swelling. This patient was a known 
diabetes mellitus which was previously diagnosed and 
undergoing treatment for past 11 years. He is an 
employee in manufacturing industry for past 7 years. He 
is on following treatment with Humalin-30/70 and in 




Diabetes mellitus along with diabetic complication (diabetic nephropathy) is well documented. There are few studies regarding 
Artificial pancreas treatment, which is the only FDA approved treatment for safe and effective way to stop and to reverse  the  
chronic  life  shortening  complications  of  diabetes. Here our main motto is to report such a case, who was presented with 
diabetic complication (particularly diabetic nephropathy) and undergoing treatment with artificial pancreatic system & to 
explain briefly with what mechanism does the artificial pancreatic system is effective in treatment or controlling the diabetic 
complications. 
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LAB INVESTIGATIONS: 
Complete Blood Picture  Liver Function Test 
Hb(g/dl) (M-11-16 F-11-14) :   10.5---decreased 
RBC(millcells/cumm)(4-6.5) : 3.5---decreased 
 WBC(cells/cumm)(4000-11000) : 7,500 
Differential Leukocyte Count 
Neutrophils(40-75%) : 65% 
Lymphocytes(20-45%) : 30% 
Eosinophils(01-06) : 5% 
Monocytes(02-10%) :2% 
Basophils(upto 1) : 




Serum Bilirubin Total(upto 1mg/dl) : 0.7 
Direct (upto 0.25mg/dl) : N 
Indirect : 
SGPT (upto 65 IU/L) : 44 
SGOT (upto 37 IU/L) :33 
Alkaline Phosphatase(15-116 IU/L) : 110 
Total Proteins (6-8gm/dl) : 7 
Albumin (3.2-5.8gm/dl) : N 
Globulin (2.2-4.8gm/dl) : N 
Lipid Profile (mg/dl) 
Total Cholesterol (140-250) : 220 
HDL Cholesterol (30-65) : 45 
LDL Cholesterol (80-180) : 90 
VLDL Cholesterol (5-45) : 35 
Triglycerides (25-160) : 140 
TC/HDL Ratio (upto 4.5) : N 
ESR (M-0-10mm/hr F-0-20mm/hr) :  
Urine Analysis 
Color : pale yellow 
Appearance : 
Pus Cells : no 
Albumin : 295 mg/day -----INCREASED 
Epithelial Cells : no 
Glucose : 
RBC : 
Biochemical Investigations (mg/dl) 
Serum Creatinine (0.6-1.4) : 2.2 mg/dl---INCREASED 
Blood Urea nitrogen (14-45) : 48-----INCREASED 
Thyroid Functions Test 
T3 (60-181 ng/dl) :  N 
T4 (7.3-15μg/dl) :   N 
TSH (0.55-4.78μIU/L) ;N 
 
DISCUSSION; 
Diabetes mellitus is a group of metabolic diseases 
characterized by hyperglycemia resulting from defects in 
insulin secretion, insulin action, or both. In this present 
case, the patient had a past history of Diabetes mellitus, 
which was previously diagnosed and undergone 
treatment for past 11 years. He is on following treatment 
with Humalin-30/70. 
Currently, the patient was admitted in the hospital with 
chief complaints of of high blood pressure, ankle and leg 
swelling. When the patient blood parameters were 
investigated, it was founded that there was a increase in 
albumin in urine (albuminuria), serum creatinine and 
blood urea nitrogen. With the subjective (symptoms) and 
objective (lab investigation) data, the patient was 
diagnose with Diabetic nephropathy. Although patient’s 
blood glucose levels were controlled to some extent by 
using humalin and other medications, there was a 
difficulty in controlling complication of diabetis mellitus. 
The pathogenesis of diabetic complications (diabetic 
nephropathy) are; 
1. Non-enzymatic protein glycosylation (Vascular) 
2. Polyol pathway mechanism. (metabolic) 
Non-enzymatic protein glycosylation;  
The free amino group of various body proteins binds by 
non-enzymatic mechanism to glucose; this process is 
called glycosylation and is directly proportionate to the 
severity of hyperglycaemia. Various body proteins 
undergoing chemical alterations in this way include 
haemoglobin, lens crystalline protein, and basement 
membrane of body cells. There is accumulation of labile 
and reversible glycosylation products on collagen and 
other tissues of the blood vessel wall which subsequently 
become stable and irreversible by chemical changes and 
form advanced glycosylation end-products (AGE). The 
AGEs bind to receptors on different cells and produce a 
variety of biologic and chemical changes e.g. thickening 
of vascular basement membrane in diabetes, which 
gradually leads to microangiopathy and decreases the 
blood flow and oxygen supply to renal cells and final 
leads to nephropathy6. 
Polyol pathway mechanism;  
This mechanism is responsible for producing lesions in 
the aorta, lens of the eye, kidney and peripheral nerves. 
These tissues have an enzyme, aldose reductase, which 
reacts with glucose to form sorbitol and fructose in the 
cells of the hyperglycaemic patient as under: 
Glucose + NADH + H+     
aldose reductase
    Sorbitol + NAD+ 
 
Sorbitol +NAD    
sorbitoldehydrogenase-Fructose   
 + NADH + H+ 
Intracellular accumulation of sorbitol and fructose is 
produced results in entry of water inside the cell and 
consequent cellular swelling and cell damage. Also, 
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intra-cellular accumulation of sorbitol causes 
intracellular deficiency of myoinositol which promotes 
injury to Schwann cells and retinal pericytes. These 
polyols result in disturbed processing of normal 
intermediary metabolites leading to complications of 
diabetes7. 
With the above mechanisms diabetes mellitus (high 
blood sugar) mainly induces or exacerbate the diabetic 
nephropathy. 
It just came to know regarding the revolutionary artificial 
pancreatic system. The artificial pancreas is a technology 
developed to help the people with diabetes to 
automatically control their blood glucose level by 
providing the substitute endocrine functionality of a 
healthy pancreas.  
The goals of the artificial pancreas are: 
1. To improve insulin replacement therapy until 
glycemic control is practically normal as evident by 
the avoidance of the complications of 
hyperglycemia, and 
2. To ease the burden of therapy for the insulin-
dependent. 
The patient was recommended to undergo artificial 
pancreatic system treatment, it was observed that 
there was a significant improvement in patients 
serum glucose levels, creatinine, albumin levels and 
restored kidney function to some extent during 
undergoing artificial pancreatic treatment( 2nd 
siiting,1week gap will be given for each sitting). 
The main mechanism that was underlying in effective 
treatment of diabetic nephropathy by artificial pancreatic 
system compared to insulin pump is; 
Generally, when a person eats carbohydrates (e.g. sugar), 
the pancreas sends oscillating pulses of insulin to the 
liver. For induction and maintenance of insulin-
dependent enzymes essential for glucose metabolism in 
the liver (e.g. hepatic glucokinase, phosphofructokinase, 
and pyruvate kinase), the hepatocytes require a defined 
insulin level (200-500 µU/ml in the portal vein) 
concomitant with high glucose levels (which acts as a 
bimolecular signal). The liver responds to this unique 
pulse pattern (insulin) by making activation of some 33 
different enzymes needed by the cells of the body to 
metabolize carbohydrates. Carbohydrate metabolism 
creates adenosine triphosphate - the chemical energy all 
cells require to accomplish their functions in the body8. 
But, for patients with diabetes mellitus (type 1& type 2) 
their liver will not receive correct oscillations and 
concentrations of insulin from the pancreas. Therefore, 
the liver does not produce and/or secrete the enzymes 
required for proper metabolism. Improper metabolism 
mainly leads to high blood sugar and causes diabetic 
microangiopathy. Microangiopathy causes the walls of 
very small blood vessels (capillaries) to become so thick 
and weak that they bleed, leak protein, and slow the flow 
of blood9. Diabetics may develop microangiopathy with 
thickening of capillaries in many areas including the 
eyes, feet, legs, and kidneys10.  
Artificial pancreas system mainly sends oscillating 
pulses of insulin to the liver and activates the insulin-
dependent enzymes essential for glucose metabolism in 
the liver (e.g. hepatic glucokinase, phosphofructokinase, 
and pyruvate kinase) . The liver responds to this unique 
pulse pattern by making some 33 different enzymes 
needed by the cells of the body to metabolize 
carbohydrates. Carbohydrate metabolism creates 
adenosine triphosphate - the chemical energy all cells 
require to accomplish their functions in the body. 
Artificial pancreas system mainly restores the proper 
carbohydrate metabolism through secretion of insulin via 
portal veins in to liver and activates the insulin 
dependent enzymes for carbohydrate metabolism, which 
is difficult to achieve with the insulin replacement 
pumps. Due to proper carbohydrate metabolism through 
artificial pancreatic system there will be decrease in 
glucose mediated non enzymatic protein glycosylation 
and polyol pathway and finally inhibits the renal damage 
or diabetic nephropathy. 
In this present case, after the artificial pancreatic system 
treatment it was observed that there was a significant 
improvement in patients serum glucose levels, creatinine, 
albumin levels and restored kidney function to some 
extent during undergoing artificial pancreatic treatment( 
2nd siiting,1week gap will be given for each sitting). 
CONCLUSION; 
According to our study we conclude that the insulin 
replacement (through insulin pumps) mainly helpful in 
maintaining blood sugar levels in a safe range, but it does 
not show any effect on the carbohydrate metabolism. 
Normal insulin pumps which is delivered other than 
intravenous route cannot achieve normal momentary 
concentration in hepatic portal veins due to which the 
insulin mediated enzymes are not activated and mainly 
results in improper carbohydrate metabolism and finally 
results in diabetic complications. But whereas artificial 
pancreas mainly simulated insulin pulses are delivered 
intravenously. Within 4 seconds, the defined insulin level 
(200-500 µU/ml in the portal vein) concomitant with 
high glucose levels (which acts as a bimolecular signal) 
enters in to the liver through hepatic portal vein and 
activates the insulin-dependent enzymes which are 
essential for glucose metabolism in the liver (e.g. hepatic 
glucokinase, phosphofructokinase, and pyruvate kinase). 
These activated enzymes mainly help full in maintaining 
proper carbohydrate metabolism and generation of ATP, 
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